Latest News

HHS effort aims to end new HIV cases within 10 years


 

FROM A HEALTH AND HUMAN SERVICES BRIEFING

Leaders from five federal agencies came together to announce the framework for a bold new national initiative that aims to eliminate new cases of HIV infection in the United States within 10 years. The announcement came the day after President Trump’s State of the Union address, which highlighted the new effort.

Courtesy U.S. Department of Health & Human Services

“HIV has cost America too much for too long,” said Adm. Brett Giroir, MD, assistant secretary for health at the Department of Health & Human Services, in a press briefing. In addition to the 700,000 U.S. lives the disease has claimed since 1981, “We are at high risk of another 400,000 becoming infected over the next decade,” with about 40,000 new infections still occurring every year, he said.

Dr. Giroir will lead a coordinated effort among HHS, the Centers for Disease Control, the National Institutes of Health, the Health Resources and Services Administration, and the Indian Health Service. The goals are to reduce new cases of HIV by 50% within 5 years, and by 90% within 10 years.

The new initiative will target 48 counties that are current hot spots for new HIV diagnoses. These 48 counties, together with Washington and San Juan, Puerto Rico, accounted for more than half of the new HIV diagnoses in 2016 and 2017, said Dr. Giroir.

“This is a laser-focused program targeting counties where infection is the highest,” said CDC Director Robert R. Redfield, MD. “We propose to deploy personnel, resources, and strategies” in these targeted areas to maximize not just diagnosis and treatment but also to reach those at risk for HIV to enroll them in preexposure prophylaxis (PrEP) regimens, he said.

In addition to the targeted counties, seven states in the rural South as well as Native American and Alaskan Native populations also will receive intensified education, diagnostic, and treatment services. The targeted states are Alabama, Arkansas, Kentucky, Mississippi, Missouri, Oklahoma, and South Carolina.

Pages

Recommended Reading

FDA seeks comments on pediatric HIV product development
MDedge Pediatrics
FDA: PrEP indication updated to include adolescents at risk of HIV infection
MDedge Pediatrics
Blood pressure meds cut cognitive impairment risk
MDedge Pediatrics
World off track for meeting 2020 HIV prevention, mortality goals
MDedge Pediatrics
Neural-tube defect signal from dolutegravir HIV treatment raises concerns
MDedge Pediatrics
In utero efavirenz, dolutegravir exposure linked to childhood neurologic problems
MDedge Pediatrics
Rate of STIs is rising, and many U.S. teens are sexually active
MDedge Pediatrics
Draft guidelines advise HIV screening for most teens and adults
MDedge Pediatrics
Temixys plus other antiretrovirals approved for HIV-1
MDedge Pediatrics
Missed HIV screening opportunities found among subsequently infected youth
MDedge Pediatrics